Coya is developing disruptive, first in class, autologous regulatory T-cell (Treg) and allogeneic exosome therapies - leveraging the seminal discoveries from the laboratory of Stanley Appel M.D., in which dysfunctional Tregs modulate neurodegenerative and autoimmune diseases.

Education

Biotechnology

Coya Therapeutics

Coya Therapeutics' headquarters in Houston, TX, United States

Howard Berman

Fred Grossman D.O., FAPA

David S. Snyder

Gregory MacMichael

Stanley Appel

Clive Svendsen

Lawrence Steinman

Anabella Villalobos

Dov Goldstein

Ann Lee

Malcolm Brenner

Shimon Sakaguchi

The Clinical Development Team at Coya Therapeutics is responsible for advancing the company's innovative therapies focused on Treg and exosome technologies for neurodegenerative and autoimmune diseases. This team collaborates across functions to design and execute clinical trials, analyze biomarker data, and ensure regulatory compliance, all while driving the translation of groundbreaking scientific discoveries into effective treatment options for patients.

Clinical Development Team

The Leadership Team at Coya Therapeutics is responsible for guiding the company’s strategic vision and operational execution in the development of innovative therapies for neurodegenerative and autoimmune diseases. Comprising key executives including the President & Chief Medical Officer, CEO, CFO, and Chief Technical Officer, the team collaborates to drive research initiatives, oversee financial stability, and ensure regulatory compliance while fostering a culture of innovation and excellence in therapeutic advancements.

Leadership Team

Coya Therapeutics

Org chart

Board & advisors

Teams

Clinical Development Team

Leadership Team

Offices

Coya Therapeutics

Org chart

Board & advisors

Teams

Clinical Development Team

Leadership Team

Offices

Related companies